Medtronic completes USD 650 million acquisition of SPR Therapeutics
MDT•Expected earnings impact
Medtronic expects the transaction to be minimally dilutive to adjusted EPS in FY27, turning neutral to accretive thereafter.
Medtronic closes SPR Therapeutics acquisition
Medtronic completed its acquisition of SPR Therapeutics for USD 650 million in upfront cash.
The deal adds SPR’s FDA-cleared SPRINT PNS System, a 60-day percutaneous peripheral nerve stimulation therapy that avoids a permanent implant.
